Streetbeat News

Products Services

SABS

SAB Biotherapeutics has received FDA clearance for its IND application to proceed with a Phase 1 trial for SAB-142, a treatment for Type 1 Diabetes.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:16 am

AZN

AstraZeneca (NASDAQ: AZN) has announced an ambitious plan to increase its total revenue to $80 billion by 2030, up from $45.8 billion in 2023. The growth will be driven by expanding its oncology, biopharmaceuticals, and rare disease portfolios, and introducing 20 new medicines by the end of the decade. The company will also invest in transformative technologies and platforms to sustain growth beyond 2030. AstraZeneca aims to achieve a mid-30s percentage core operating margin by 2026 and maintain it post-2026. Analysts have mixed views on the revenue target, with some seeing a 20% upside to the 2030 consensus.

Portfolio Pulse from Vandana Singh

May 21, 2024 | 11:16 am

CLSD

Clearside Biomedical has announced the publication of consensus guidelines for drug delivery via suprachoroidal space (SCS) injection in the peer-reviewed journal RETINA. An expert panel of ophthalmologists developed these guidelines, which support SCS injection as a safe and effective method for delivering retinal and choroidal therapeutics.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:13 am

NABL

N-able and MSPAlliance have partnered to assist Managed Service Providers (MSPs) in navigating cybersecurity compliance requirements. This collaboration aims to provide MSPs with the necessary tools and resources to meet regulatory standards and enhance their cybersecurity posture.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:12 am

AMZN

VERI

Veritone's AI-powered solutions for the public sector are now available in the AWS Marketplace, potentially expanding their reach and customer base.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:10 am

AIRI

Air Industries Group has received a $2.4 million order for landing gear used on the E-2C Hawkeye.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:09 am

GLUE

Monte Rosa Therapeutics will present preclinical data at Digestive Disease Week 2024, showing that MRT-6160-mediated degradation of VAV1 inhibited disease progression in a T-cell transfer murine model of colitis. VAV1 is a key signaling protein with potential to treat multiple autoimmune and inflammatory diseases.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:09 am

MBC

MasterBrand is set to acquire Supreme Cabinetry Brands, a manufacturer of premier cabinet brands. This acquisition is expected to enhance MasterBrand's product portfolio and market presence.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:07 am

ASLN

ASLAN Pharmaceuticals announced a late-breaking poster presentation of translational data on eblasakimab at the American Thoracic Society International Conference.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:07 am

LASE

Laser Photonics has launched the next generation of its CleanTech Laser Cleaning Systems, which are designed to provide more efficient and environmentally friendly cleaning solutions.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:03 am